Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study (vol 22, pg 489, 2021)

被引：0
|
作者：
Rugo, H. S.
Lerebours, F.
Ciruelos, E.
机构：
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E184 / E184
页数：1
相关论文
共 50 条
  • [21] PIK3CA-mutated (mut) hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) previously treated with cyclin-dependent kinase 4/6 inhibitor (CDKi) plus aromatase inhibitor (AI): BYLieve study results.
    Rugo, Hope S.
    Lerebours, Florence
    Ciruelos, Eva
    Drullinsky, Pamela
    Borrego, Manuel Ruiz
    Neven, Patrick
    Park, Yeon Hee
    Prat, Aleix
    Bachelot, Thomas
    Juric, Dejan
    Turner, Nicholas C.
    Sophos, Nickolas
    Zarate, Juan Pablo
    Arce, Christina
    Shen, Yu-Ming
    Chia, Stephen K. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [22] Impact of ESR1 mutations on endocrine therapy (ET) plus alpelisib benefit in patients with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated, advanced breast cancer (ABC) who progressed on or after prior cyclin-dependent kinase inhibitor (CDK4/6i) therapy in the BYLieve trial
    Turner, Nick
    Rugo, Hope S.
    Ciruelos, Eva M.
    Ruiz-Borrego, Manuel
    Drullinsky, Pamela
    Lerebours, Florence
    Prat, Aleix
    Bachelot, Thomas
    Chia, Stephen
    Balbin, Alejandro
    Joshi, Mukta
    Roux, Estelle
    Arce, Christina H.
    Akdere, Murat
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
  • [23] Baseline and End-of-Treatment Biomarkers in Patients With PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From BYLieve Study Cohorts A and B
    Juric, Dejan
    Turner, Nicholas
    Loi, Sherene
    Andre, Fabrice
    Chia, Stephen K.
    Jhaveri, Komal
    Neven, Patrick
    Dent, Rebecca
    Ciruelos, Eva
    Joshi, Mukta
    Roux, Estelle
    Patino, Heather
    Akdere, Murat
    Rugo, Hope
    CANCER RESEARCH, 2023, 83 (05)
  • [24] Alpelisib (ALP) plus endocrine therapy (ET) by last prior therapy in patients (pts) with PIK3CA-mutated hormone-receptor positive (HR plus ) human epidermal growth factor receptor-2-Negative (HER2-) advanced breast cancer (ABC): Additional study cohort in BYLieve
    Ciruelos, E.
    Lerebours, F.
    Ruiz Borrego, M.
    Bachelot, T.
    Polikoff, J.
    Chia, S.
    Juric, D.
    Turner, N.
    Ridolfi, A.
    Sophos, N.
    Cooper, B.
    Thuerigen, A.
    Rugo, H. S.
    ANNALS OF ONCOLOGY, 2019, 30 : 141 - 141
  • [25] Preventing alpelisib-related hyperglycaemia in HR+/HER2-/ PIK3CA-mutated advanced breast cancer using metformin (METALLICA): a multicentre, open-label, single-arm, phase 2 trial
    Llombart-Cussac, Antonio
    Perez-Garcia, Jose Manuel
    Borrego, Manuel Ruiz
    Tolosa, Pablo
    Blanch, Salvador
    Fernandez-Ortega, Adela
    Urruticoechea, Ander
    Blancas, Isabel
    Saura, Cristina
    Rojas, Beatriz
    Bermejo, Begona
    Lorenzo, Jose Ponce
    Gion, Maria
    Cortez-Castedo, Patricia
    Llabres, Elisenda
    Galve, Elena
    Cueva, Juan Fernando
    Lopez, Ana
    Alonso-Romero, Jose Luis
    Gonzalez-Santiago, Santiago
    de Duenas, Eduardo Martinez
    Ciruelos, Eva
    Martrat, Griselda
    Gener, Petra
    Alcala-Lopez, Daniel
    Sampayo-Cordero, Miguel
    Gomez-Peralta, Fernando
    Cortes, Javier
    ECLINICALMEDICINE, 2024, 71
  • [26] Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for PIK3CA-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast Cancer
    Jhaveri, Komal L.
    Accordino, Melissa K.
    Bedard, Philippe L.
    Cervantes, Andres
    Gambardella, Valentina
    Hamilton, Erika
    Italiano, Antoine
    Kalinsky, Kevin
    Krop, Ian E.
    Oliveira, Mafalda
    Schmid, Peter
    Saura, Cristina
    Turner, Nicholas C.
    Varga, Andrea
    Cheeti, Sravanthi
    Hilz, Stephanie
    Hutchinson, Katherine E.
    Jin, Yanling
    Royer-Joo, Stephanie
    Peters, Ubong
    Shankar, Noopur
    Schutzman, Jennifer L.
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (33)
  • [27] Metformin (MET) for the prevention of Alpelisib (ALP)-related Hyperglycemia (HG) in PIK3CA-mutated, Hormone Receptor-Positive (HR[+]) HER2-Negative (HER2[-]) Advanced Breast Cancer (ABC): The METALLICA study
    Borrego, Manuel Ruiz
    Tolosa, Pablo
    Blanch, Salvador
    Fernandez, Adela
    Urriticoechea, Ander
    Blancas, Isabel
    Saura, Cristina
    Rojas, Beatriz
    Bermejo, Begona
    Ponce, Jose
    Gion, Maria
    Llabres, Elisenda
    Galve, Elena
    Cueva, Juan Fernando
    Lopez, Ana
    Alonso-Romero, Jose L.
    Gonzalez-Santiago, Santiago
    De Duenas, Eduardo Martinez
    Peralta, Fernando Gomez
    Ciruelos, Eva
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    CANCER RESEARCH, 2023, 83 (05)
  • [28] BioItaLEE: Molecular features of postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) PIK3CA-mutated advanced breast cancer (ABC) on first-line treatment with ribociclib plus letrozole and on second-line treatment with alpelisib plus fulvestrant
    Allegrini, G.
    Orditura, M.
    Del Mastro, L.
    Zamagni, C.
    Torrisi, R.
    Guarneri, V.
    Paris, I.
    Sarobba, G.
    Puglisi, F.
    Colleoni, M. A.
    Montemurro, F.
    Zambelli, A.
    Cazzaniga, M. E.
    Valerio, M. R.
    Bianchi, G.
    Romagnoli, E.
    Caruso, M.
    Cinieri, S.
    Castelletti, D.
    Arpino, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S302 - S302
  • [29] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-) PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva M.
    Bianchini, Giampaolo
    Barrios, Carlos H.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [30] INAVO121: Phase III study of inavolisib (INAVO) plus fulvestrant (FUL) vs. alpelisib (ALP) plus FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2-), PIK3CA-mutated (mut) locally advanced or metastatic breast cancer (LA/mBC)
    Juric, Dejan
    Kalinsky, Kevin
    Im, Seock-Ah
    Ciruelos, Eva
    Bianchini, Giampaolo
    Barrios, Carlos H., Sr.
    Jacot, William
    Schmid, Peter
    Loi, Sherene
    Rugo, Hope S.
    Craine, Veronica
    Hutchinson, Katherine E.
    Flechais, Aulde
    Thanopoulou, Eirini
    Harbeck, Nadia
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345